The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
about
Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survivalProteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle controlSpecific small molecule inhibitors of Skp2-mediated p27 degradationSkp2: a novel potential therapeutic target for prostate cancerNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyRSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.PKCdelta regulates cortical radial migration by stabilizing the Cdk5 activator p35The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell linesThe role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implicationsNodal signaling promotes a tumorigenic phenotype in human breast cancerFunctional O-GlcNAc modifications: implications in molecular regulation and pathophysiologyUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastomaCaspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasionMechanism of p27 Unfolding for CDK2 Reactivation.Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapyAPC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathwayCross Talk between the Calcium-Sensing Receptor and the Vitamin D System in Prevention of CancerCombined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1)The N-terminal region of p27 inhibits HIF-1α protein translation in ribosomal protein S6-dependent manner by regulating PHLPP-Ras-ERK-p90RSK axisOccupational exposure to carcinogens: Benzene, pesticides and fibers (Review)Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell deathOverexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progressionGatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53Reduced expression of the retinoblastoma protein shows that the related signaling pathway is essential for mediating the antineoplastic activity of erufosineHigh-throughput screening reveals alsterpaullone, 2-cyanoethyl as a potent p27Kip1 transcriptional inhibitorIdentifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive SetsAnimal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 YearsThe landscape of cancer genes and mutational processes in breast cancerIn Vivo Interplay between p27Kip1, GATA3, ATOH1, and POU4F3 Converts Non-sensory Cells to Hair Cells in Adult Mice.Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cellsThe yin-yang of DNA damage response: roles in tumorigenesis and cellular senescence.Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.p27(Kip1) controls cytokinesis via the regulation of citron kinase activation.PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells.An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stressTherapeutic implications of GIPC1 silencing in cancerLuminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingSarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
P2860
Q21090556-32E6A6BE-7DC6-42EA-BE6A-AF3A6D6AA749Q24294703-DAA043A8-01FB-4D63-81A1-CCE874746A0CQ24297854-5BAEA8BC-46A0-4AF8-A4C1-1C3098C0D9B6Q24596988-02021E89-EFCB-4729-82D4-F2965564FE14Q24625558-95C7829F-BA05-436E-A540-E6FD435D3767Q24628724-ACE2CD8D-965F-4BAB-8E0F-DD27AEAB3215Q24647282-642666E0-F75E-464D-925F-D95481F4E7FEQ24651948-30075106-B527-44FD-BB0B-33E1785334C9Q24655583-1E2DD384-AEC9-4B59-B08A-5CE8A02E4205Q26783814-4167A853-7A02-43DB-AFE9-70583A2F477CQ26826854-BD253832-8CBC-47BA-B9A6-4BF01F16995CQ27009399-C0828E19-C053-4327-97F9-97161C1D62C2Q27011911-0F8A95A1-4D99-4B47-8CB3-B0D377787AFDQ27309926-6FCF33AA-6CBB-470E-86C8-805399F822DBQ27313253-F64FB996-FAE6-4E76-B9EA-EDF01B538D2EQ27853119-137AE2E9-A39A-4331-BEED-012A47FA2B50Q28072560-35C9C36D-18EE-430D-9250-C9F14BD76328Q28078250-616D61D7-A409-4D22-AFB8-05B152D0A480Q28240913-6B7ADA5F-C1C8-4648-9029-AE487614FB8CQ28258201-B5E6D1A8-2DA8-462F-973C-464FFCB663C1Q28383901-96798BBA-8213-41FC-A64B-8AE022B25F27Q28393587-B590F8EF-8102-4B55-99E2-2B4C46D18571Q28482928-5045D896-D447-405B-8D96-38BA23D9AC3BQ28483701-C0F138E4-26B9-4440-956D-F275CD1649EAQ28484635-EB63FFFD-EDF7-4EE4-A80C-88BBD84CED6EQ28540246-44CE188D-0494-4B54-A5B9-1473726F95EDQ28541113-94EE5281-C274-4851-8510-9B330E6E45BAQ28608346-799A9A2A-FC8E-461C-937B-2FFB0C117A16Q28829867-47CA8BC5-A3C1-437E-81AF-3E586238E519Q29614637-9C9FEF2F-71E4-4855-BA16-4E37D5380E00Q30356971-C9E125F9-9414-431D-ABB9-A941A23618DFQ30414074-0288F266-CCA8-4AEF-8102-96989F75E9E4Q30426400-AD1EC88D-B194-47EC-AEBC-2F777237AF55Q30446755-E7B1AD40-8962-451D-A1CD-69D105C1CF35Q30505731-CB32BF9D-3A5E-4BFC-8518-46112C82CF93Q30593254-0F319CDB-F163-4A5C-A12B-D5635F38787AQ30824986-E83C3695-1CCD-4CB9-98BC-AE7F55E48363Q30994062-F39BE54B-80CB-412F-8458-2F2C2D562C29Q31132241-9207666D-20F1-4533-8466-8001F26395ECQ33364225-F2233074-7EA2-44AA-A849-AD014CCC7CF3
P2860
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@ast
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@en
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@nl
type
label
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@ast
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@en
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@nl
prefLabel
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@ast
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@en
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@nl
P2093
P356
P1476
The Cdk inhibitor p27 in human ...... levance to anticancer therapy.
@en
P2093
Isabel M Chu
Joyce M Slingerland
Ludger Hengst
P2888
P304
P356
10.1038/NRC2347
P407
P577
2008-04-01T00:00:00Z
P6179
1046912140